STRATEGIC NEWS WATCH — August 21, 2026
|
Johnson & Johnson’s full EU approval of Tecvayli–daratumumab in second-line myeloma expands a bispecific’s addressable market at CAR-T’s expense, while HHS’s move to reopen the federal vaccine-category rulebook threatens to redraw which vaccines carry coverage-triggering recommendations. Today’s top developments:
|
What to Watch
- Tecvayli’s second-line uptake vs. CAR-T — With an HR of 0.17 on progression-free survival and an off-the-shelf, steroid-sparing profile, the open question is whether EU myeloma guidelines move teclistamab–daratumumab ahead of BCMA CAR-T in second line, and whether step-up dosing and infection-monitoring requirements confine use to centres with bispecific experience.
- MHRA licensing of Onswik — NICE’s recommendation is conditional on a UK marketing authorisation Lilly has applied for but not yet received; the MHRA decision is the next gate, and it remains to be seen whether the phased-rollout, dosing-error safeguards specialists asked for survive into final guidance.
- HHS vaccine RFI comment window — Comments close 30 days from the August 21 posting; the key uncertainty is whether HHS proceeds to rulemaking or ACIP process changes, and whether any recategorization touches Vaccines for Children eligibility or ACA preventive-coverage mandates — the mechanisms that convert recommendation status into manufacturer revenue.
- GLP-1 price competition — With cost cited as the driver of most discontinuations, cash-pay list moves on the oral entrants and 2027 employer-plan coverage decisions bear tracking, and will matter more to volume than any further efficacy differentiation.
- Onshoring timelines vs. tariff timelines — Roche’s Oregon expansion is not operational until 2031 and is far from the only pledge on that horizon; the real test is whether tariff relief keeps being granted on announced investment rather than delivered capacity.
This brief highlights the edition’s top stories. Read the full August 21, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.